Doctors Flag Cannabis as Possible Psoriasis Trigger

Cannabis has attracted growing attention for its anti-inflammatory potential, with researchers increasingly investigating cannabinoids as possible therapeutics for chronic skin conditions such as psoriasis. But what happens when a substance being studied as a treatment appears to trigger the very condition it may one day help manage?

A dermatology case report¹ explores that question after documenting a patient who developed biopsy-supported drug-induced psoriasis shortly after smoking cannabis, with recurrence following exposure to a different cannabis strain. While the report describes only a single patient and does not necessarily prove that cannabis commonly causes psoriasis, it highlights an important clinical lesson: as medical and recreational cannabis use continues to expand, healthcare providers may need to consider cannabis exposure when evaluating unexplained or recurring psoriasis flares.

The findings are not intended to cause alarm or undermine the growing body of research investigating cannabinoids as potential dermatological therapies. Instead, they reinforce an important principle of medicine, that any biologically active compound capable of producing therapeutic effects may also produce rare adverse reactions in certain individuals. Let’s dive into the case study and what needs to happen next in dermatology cannabis research.

Psoriasis Triggers

Psoriasis is a chronic inflammatory autoimmune disease that causes well-defined, scaly patches of skin that commonly appear on the elbows, knees, scalp, trunk, and other areas of the body. Although genetics plays an important role, the disease often develops through a combination of inherited risk and environmental triggers. These include infections, physical injury to the skin, psychological stress, hormonal and metabolic changes, lifestyle factors, and certain medications.

Drug-induced psoriasis is already well recognized in dermatology. Medications such as lithium, beta blockers, antimalarials, antibiotics, and several other drug classes have been associated with psoriasis flares in susceptible individuals. Cannabis, however, has rarely been considered among these potential triggers, making this newly reported case especially noteworthy.

A Rare Case That Caught Physicians’ Attention

The case involved a 37-year-old man who developed an intensely itchy, scaly rash involving his arms, legs, trunk, buttocks, and underarms within 24 to 48 hours after smoking cannabis. What made this case particularly compelling was its pattern. The patient initially experienced the eruption after chronic recreational cannabis use. About one month later, the rash returned after he smoked a different cannabis strain obtained from another dispensary, suggesting the reaction was not limited to a single product. During his medical evaluation, physicians carefully ruled out other common psoriasis triggers, including medications, infections, mechanical stress, environmental exposures, psychological stress, and hormonal or metabolic changes.

A skin biopsy revealed classic features consistent with psoriasis. Based on the clinical history, biopsy findings, and exclusion of alternative causes, physicians diagnosed the patient with drug-induced psoriasis. Treatment with topical clobetasol cream twice daily for two weeks resulted in complete resolution of the rash, and the patient was advised to avoid cannabis to help prevent future recurrences.

Why This Case Matters

Importantly, the authors are not arguing that cannabis commonly causes psoriasis. Rather, they suggest clinicians should consider cannabis exposure as one possible factor when evaluating patients whose psoriasis develops or repeatedly flares soon after cannabis use.

Although this report describes only a single patient, rare adverse reactions often become apparent only after a medication or substance is used by large numbers of people. As cannabis legalization expands worldwide, physicians are likely to encounter increasingly diverse patient experiences, including uncommon reactions that previously may have gone unnoticed. Recognizing those possibilities allows clinicians to ask better questions, identify potential triggers more efficiently, and provide more personalized care without overstating the risks.

Cannabis and Skin Biology Are Complex

The report is especially interesting because cannabis has also been investigated as a possible treatment for inflammatory skin diseases, including psoriasis.

The skin contains cannabinoid receptors that help regulate inflammation, immune activity, skin-cell growth, and skin barrier function. Previous laboratory studies and systematic reviews have suggested cannabinoids may reduce itching and possess anti-inflammatory properties that could prove beneficial for psoriasis. However, clinical evidence remains limited. While some studies have reported modest improvements in symptoms such as pruritus, larger randomized clinical trials have not yet established consistent benefits for other important outcomes, including redness, skin dryness, or overall quality of life.

The complexity of cannabis may help explain these mixed findings. The plant contains more than 125 phytocannabinoids, along with hundreds of additional compounds such as terpenes that may influence biological activity. A compound that appears anti-inflammatory in one person or one disease setting may not behave identically in every individual. Differences in genetics, immune function, dose, cannabinoid profile, terpene composition, and route of administration could all influence how someone responds to cannabis.

Researchers Still Don’t Know Why It Happens

Perhaps the most important message from the study is how much researchers still have to learn. The biological mechanisms responsible for cannabis-induced psoriasis have not been fully established. The authors outline several possible explanations, including immune modulation, oxidative stress, alterations in inflammatory cytokine signaling, and individual genetic susceptibility. At this stage, however, these remain scientific hypotheses rather than proven mechanisms.

Researchers also acknowledge that critical questions remain unanswered. They do not yet know whether certain cannabinoid profiles, terpene combinations, cannabis chemovars, doses, or methods of consumption influence risk. In this case, the patient’s exposure occurred through inhaled cannabis, but future studies will need to investigate edible, topical, sublingual, and other delivery methods as well.

Animal research cited by the authors has also suggested that certain cannabinoids may alter skin barrier function under specific experimental conditions. While these findings cannot be directly applied to humans, they provide additional clues that warrant further investigation.

Ultimately, much larger clinical studies will be needed to determine how frequently this rare phenomenon occurs, identify which patients may be susceptible, and better understand the biological pathways involved.

Final Thoughts

This case report should not be interpreted as evidence that cannabis commonly causes psoriasis. Millions of people use cannabis without experiencing this type of reaction, and research into cannabinoids as potential therapies for inflammatory skin diseases continues to evolve. Instead, the report highlights an important reality of modern cannabis medicine, that therapeutic potential and rare adverse reactions can exist simultaneously.

For clinicians, the findings reinforce the value of asking patients about cannabis use when evaluating unexplained or recurring psoriasis flares. Researchers underscore the need to better understand who may be vulnerable, why these reactions occur, and whether specific cannabis compounds or patterns of use influence risk.

As cannabis becomes more widely used around the world, balancing its therapeutic promise with careful investigation of uncommon adverse events will help build a more complete understanding, leading to safer, more personalized care for patients.